Current Heart Failure Reports

, Volume 9, Issue 3, pp 244–251 | Cite as

Mid-Regional Pro-Adrenomedullin in Acute Heart Failure: A Better Biomarker or Just Another Biomarker?

  • Mihael PotockiEmail author
  • Ronny Ziller
  • Christian Mueller
Decompensated Heart Failure (MM Givertz, Section editor)


Circulating biomarkers have become increasingly important in diagnosing and risk-stratifying patients with heart failure (HF). While the natriuretic peptides have received much focus in the past decade, there is increasing interest in the role of other circulating biomarkers such as mid-regional proadrenomedullin (MR-proADM), a stable peptide of the precursor of adrenomedullin (ADM), responsible for volume regulation and electrolyte homeostasis. Increased levels of MR-proADM are associated with an increased risk of mortality and morbidity in patients with HF, independent of natriuretic peptides. MR-proADM outperforms all other established markers in the identification of patients at highest risk of death, particularly death within 30 days. The prognostic superiority has consistently been shown for various cardiovascular disease states, including acute heart failure. In this article, we discuss the potential role of MR-proADM in the syndrome of acute heart failure and its implication on prognosis and risk stratification.


MR-proADM Adrenomedullin Heart failure Prognosis Biomarkers 



Dr. Mihael Potocki and Dr. Christian Mueller were supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the Novartis Foundation, the Krokus Foundation, Abbott, Alere (Biosite), Brahms, Roche, and the University of Basel .Dr. Christian Mueller has also received payment for lectures (including service on speakers bureaus) from Roche, Abbott Laboratories, Alere, Novartis, and Siemens. R. Ziller: none.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.Google Scholar
  2. 2.
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Januzzi Jr JL, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo Jr CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Peacock WFt, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble st2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997;95:1214–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Nicholls MG, Charles CJ, Lainchbury JG, Lewis LK, Rademaker MT, Richards AM, Yandle TG. Adrenomedullin in heart failure. Hypertens Res. 2003;26(Suppl):S135–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 1996;81:180–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma n-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138–67.PubMedCrossRefGoogle Scholar
  13. 13.
    Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Khan SQ, O’Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Bergmann A, Ng LL. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the lamp (leicester acute myocardial infarction peptide) study. J Am Coll Cardiol. 2007;49:1525–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of b-type natriuretic peptide, mid-regional pro-a-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13:42–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, Elmas E, Hoffmann U, Borggrefe M, Brueckmann M. Long-term prognostic value of mid-regional pro-adrenomedullin and c-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med. 2008;46:204–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Adlbrecht C, Hulsmann M, Strunk G, Berger R, Mortl D, Struck J, Morgenthaler NG, Bergmann A, Jakowitsch J, Maurer G, Lang IM, Pacher R. Prognostic value of plasma midregional pro-adrenomedullin and c-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail. 2009;11:361–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Gombos T, Forhecz Z, Pozsonyi Z, Wallentin S, Papassotiriou J, Kunde J, Morgenthaler NG, Janoskuti L, Prohaszka Z. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm Res. 2009;58:298–305.PubMedCrossRefGoogle Scholar
  19. 19.
    Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care. 2009;13:R122.PubMedCrossRefGoogle Scholar
  20. 20.
    Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L, Investigators G-H. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the gissi-heart failure (gissi-hf) trial. Eur J Heart Fail. 2010;12:338–47.PubMedCrossRefGoogle Scholar
  21. 21.
    von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler NG, Anker SD. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12:484–91.CrossRefGoogle Scholar
  22. 22.
    Klip IT, Voors AA, Anker SD, Hillege HL, Struck J, Squire I, van Veldhuisen DJ, Dickstein K, OPTIMAAL Investigators. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart. 2011;97:892–8.Google Scholar
  23. 23.
    •• Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2011;58:1057–67. This prospective, multicenter, international study included 1,641 patients presenting to the emergency department with dyspnea. In the subgroup of 568 patients diagnosed with acute heart failure, MR-proADM was superior to BNP and NT-proBNP for predicting 90-day mortality and especially 30-day mortality.PubMedCrossRefGoogle Scholar
  24. 24.
    Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011;18:947–58.PubMedCrossRefGoogle Scholar
  25. 25.
    Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55:2062–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Shimosawa T, Fujita T. Adrenomedullin and its related peptide. Endocr J. 2005;52:1–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Kitamura K, Kangawa K, Ishiyama Y, Washimine H, Ichiki Y, Kawamoto M, Minamino N, Matsuo H, Eto T. Identification and hypotensive activity of proadrenomedullin n-terminal 20 peptide (pamp). FEBS Lett. 1994;351:35–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Watanabe TX, Itahara Y, Inui T, Yoshizawa-Kumagaye K, Nakajima K, Sakakibara S. Vasopressor activities of n-terminal fragments of adrenomedullin in anesthetized rat. Biochem Biophys Res Commun. 1996;219:59–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Gumusel B, Hao Q, Hyman AL, Kadowitz PJ, Champion HC, Chang JK, Mehta JL, Lippton H. Analysis of responses to adrenomedullin-(13–52) in the pulmonary vascular bed of rats. Am J Physiol. 1998;274:H1255–63.PubMedGoogle Scholar
  30. 30.
    Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International union of pharmacology. Xxxii. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233–46.PubMedCrossRefGoogle Scholar
  31. 31.
    Lopez J, Martinez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol. 2002;221:1–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Tomoda Y, Isumi Y, Katafuchi T, Minamino N. Regulation of adrenomedullin secretion from cultured cells. Peptides. 2001;22:1783–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Zhou M, Chaudry IH, Wang P. The small intestine is an important source of adrenomedullin release during polymicrobial sepsis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R654–60.PubMedGoogle Scholar
  34. 34.
    Zhou M, Chaudry IH, Wang P. Adrenomedullin is upregulated in the heart and aorta during the early and late stages of sepsis. Biochim Biophys Acta. 1999;1453:273–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Washimine H, Asada Y, Kitamura K, Ichiki Y, Hara S, Yamamoto Y, Kangawa K, Sumiyoshi A, Eto T. Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue. Histochem Cell Biol. 1995;103:251–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Ishimitsu T, Miyata A, Matsuoka H, Kangawa K. Transcriptional regulation of human adrenomedullin gene in vascular endothelial cells. Biochem Biophys Res Commun. 1998;243:463–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201:1160–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Meeran K, O’Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, Bloom SR. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab. 1997;82:95–100.PubMedCrossRefGoogle Scholar
  39. 39.
    Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1–52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem. 1998;44:571–7.PubMedGoogle Scholar
  40. 40.
    Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, Eto T. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol. 1993;241:271–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett Jr JC. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997;273:R1392–9.PubMedGoogle Scholar
  43. 43.
    Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab. 2000;85:1016–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Secretion of proadrenomedullin n-terminal 20 peptide from cultured neonatal rat cardiac cells. Life Sci. 2001;69:239–45.PubMedCrossRefGoogle Scholar
  45. 45.
    Chun TH, Itoh H, Saito T, Yamahara K, Doi K, Mori Y, Ogawa Y, Yamashita J, Tanaka T, Inoue M, Masatsugu K, Sawada N, Fukunaga Y, Nakao K. Oxidative stress augments secretion of endothelium-derived relaxing peptides, c-type natriuretic peptide and adrenomedullin. J Hypertens. 2000;18:575–80.PubMedCrossRefGoogle Scholar
  46. 46.
    Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J, Nakao K. Shear stress augments expression of c-type natriuretic peptide and adrenomedullin. Hypertension. 1997;29:1296–302.PubMedCrossRefGoogle Scholar
  47. 47.
    Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem. 1998;273:17787–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res. 2003;26(Suppl):S121–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Hirata Y, Hayakawa H, Suzuki Y, Suzuki E, Ikenouchi H, Kohmoto O, Kimura K, Kitamura K, Eto T, Kangawa K, et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. Hypertension. 1995;25:790–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension. 1998;31:505–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Inatsu H, Sakata J, Shimokubo T, Kitani M, Nishizono M, Washimine H, Kitamura K, Kangawa K, Matsuo H, Eto T. Distribution and characterization of rat immunoreactive proadrenomedullin n-terminal 20 peptide (pamp) and the augmented cardiac pamp in spontaneously hypertensive rat. Biochem Mol Biol Int. 1996;38:365–72.PubMedGoogle Scholar
  52. 52.
    Romppanen H, Marttila M, Magga J, Vuolteenaho O, Kinnunen P, Szokodi I, Ruskoaho H. Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: blunted effect in experimental hypertension. Endocrinology. 1997;138:2636–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, Matsuo H, Kangawa K. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension. 1997;30:1369–75.PubMedCrossRefGoogle Scholar
  54. 54.
    Niu P, Shindo T, Iwata H, Iimuro S, Takeda N, Zhang Y, Ebihara A, Suematsu Y, Kangawa K, Hirata Y, Nagai R. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation. 2004;109:1789–94.PubMedCrossRefGoogle Scholar
  55. 55.
    Kawai J, Ando K, Tojo A, Shimosawa T, Takahashi K, Onozato ML, Yamasaki M, Ogita T, Nakaoka T, Fujita T. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation. 2004;109:1147–53.PubMedCrossRefGoogle Scholar
  56. 56.
    Jougasaki M, Wei CM, McKinley LJ, Burnett Jr JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995;92:286–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Hamada M, Shigematsu Y, Kawakami H, Minamino N, Kangawa K, Matsuo H, Hiwada K. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-i, natriuretic peptides and noradrenaline. Clin Sci (Lond). 1998;94:21–8.Google Scholar
  58. 58.
    Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond). 1997;92:467–72.Google Scholar
  59. 59.
    Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498–503.PubMedCrossRefGoogle Scholar
  60. 60.
    Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-a-type natriuretic peptide concentrations in healthy individuals. Biomarkers. 2011;16:281–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Li Y, Jiang C, Wang X, Zhang Y, Shibahara S, Takahashi K. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides. 2007;28:1129–43.PubMedCrossRefGoogle Scholar
  62. 62.
    Shimosawa T, Ogihara T, Matsui H, Asano T, Ando K, Fujita T. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension. 2003;41:1080–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, Haltmayer M, Kronenberg F, Group MS. Pro-a-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the mmkd study. Kidney Int. 2009;75:408–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786–92.PubMedCrossRefGoogle Scholar
  65. 65.
    Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-b-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206–12.PubMedCrossRefGoogle Scholar
  66. 66.
    Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of b-type natriuretic peptide for risk assessment in unstable angina/non-st-elevation myocardial infarction: B-type natriuretic peptide and prognosis in tactics-timi 18. J Am Coll Cardiol. 2003;41:1264–72.PubMedCrossRefGoogle Scholar
  67. 67.
    Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, Tzikas S, Lackner KJ, Peetz D, Rupprecht HJ, Bickel C, Morgenthaler NG, Papassotiriou J, Tiret L, Munzel T, Blankenberg S. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the atherogene study. Clin Chem. 2012;58:226–36.PubMedCrossRefGoogle Scholar
  68. 68.
    Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995;26:1424–31.PubMedCrossRefGoogle Scholar
  69. 69.
    Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG. Plasma n-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-new zealand heart failure group. J Am Coll Cardiol. 2001;37:1781–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, Thomas D, Komajda M. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J. 2000;21:1009–14.PubMedCrossRefGoogle Scholar
  71. 71.
    Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, Tu JV, Stukel TA. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010;3:228–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Mihael Potocki
    • 1
    Email author
  • Ronny Ziller
    • 1
  • Christian Mueller
    • 1
  1. 1.Department of CardiologyUniversity HospitalBaselSwitzerland

Personalised recommendations